Biomea Fusion doses first patient with type 1 diabetes in COVALENT-112 trial

Biomea Fusion announced dosing of the first patient with type 1 diabetes in the U.S. in its ongoing Phase II study, COVALENT-112, evaluating BMF-219, a novel, investigational covalent menin inhibitor, as a potential treatment for patients with type 1 diabetes. “We are very excited to announce this milestone of starting the enrollment in our clinical trial for adults with type 1 diabetes, where a great unmet need exists. Persons with type 1 diabetes require exogenous insulin therapy, which entails intensive management and can result in important morbidity, including hypoglycemia and weigh gain. With the encouraging data from our preclinical and early-phase clinical studies of BMF-219 in type 2 diabetes, we believe that by targeting one of the root causes of diabetes, this oral agent has the potential to restore the health and function of the body’s own mechanism to produce insulin, the beta cells,” stated Juan Pablo Frias, MD, Biomea Fusion’s Chief Medical Officer. He added, “We look forward to presenting initial data in 2024 as we march toward our goal of delivering a transformational therapy for patients with diabetes.”